China Historical Income Statement

000503 Stock

12.12 0.70 5.46%

Historical analysis of China Reform income statement accounts such as Selling General Administrative of 77.9 M, Total Revenue of 199 M or Cost Of Revenue of 299.6 M can show how well China Reform Health performed in making a profits. Evaluating China Reform income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of China Reform's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining China Reform Health latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether China Reform Health is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Reform Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About China Income Statement Analysis

China Reform Health Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to China Reform shareholders. The income statement also shows China investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

China Reform Income Statement Chart

At present, China Reform's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 77.9 M, whereas Total Revenue is forecasted to decline to about 199 M.

Selling General Administrative Total Revenue Cost Of Revenue Income Tax Expense

Total Revenue

Total revenue comprises all receipts China Reform Health generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Cost Of Revenue

Cost of Revenue is found on China Reform Health income statement and represents the costs associated with goods and services China Reform provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from China Reform's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into China Reform Health current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Reform Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2024	2025 (projected)
Discontinued Operations	169.8M	150.9M
Research Development	871.2K	827.6K

Discontinued Operations Research Development

China Reform income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Minority Interest	Research Development	Discontinued Operations	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		-0.14	0.34	-0.62	0.61	0.58	0.74	0.14	0.59	0.06	0.59	0.81	0.61	0.47	-0.28	0.75	0.75	0.36	0.36	0.6	-0.05
Total Revenue	-0.14		0.33	0.53	0.13	0.12	-0.06	-0.11	0.05	-0.03	0.53	0.06	0.03	0.26	0.51	0.05	-0.06	-0.43	-0.44	0.04	0.42
Operating Income	0.34	0.33		-0.31	0.63	0.61	0.21	0.37	0.61	0.08	0.46	0.66	0.56	0.25	-0.46	0.66	0.5	0.42	0.43	0.54	-0.12
Cost Of Revenue	-0.62	0.53	-0.31		-0.4	-0.38	-0.5	-0.21	-0.71	-0.56	0.01	-0.72	-0.42	-0.2	0.65	-0.67	-0.73	-0.8	-0.79	-0.41	0.56
Income Before Tax	0.61	0.13	0.63	-0.4		1.0	0.54	-0.19	0.52	0.12	0.41	0.74	0.98	0.49	-0.4	0.66	0.75	0.42	0.45	0.98	-0.09
Net Income	0.58	0.12	0.61	-0.38	1.0		0.5	-0.23	0.51	0.11	0.39	0.71	0.99	0.49	-0.39	0.63	0.72	0.4	0.43	0.99	-0.08
Income Tax Expense	0.74	-0.06	0.21	-0.5	0.54	0.5		0.08	0.39	0.26	0.29	0.72	0.48	0.5	-0.36	0.73	0.75	0.55	0.55	0.47	-0.24
Minority Interest	0.14	-0.11	0.37	-0.21	-0.19	-0.23	0.08		0.1	0.01	0.01	0.11	-0.22	-0.42	-0.35	0.2	-0.07	0.24	0.24	-0.24	-0.13
Research Development	0.59	0.05	0.61	-0.71	0.52	0.51	0.39	0.1		0.45	0.34	0.84	0.46	0.28	-0.45	0.71	0.76	0.59	0.57	0.45	-0.28
Discontinued Operations	0.06	-0.03	0.08	-0.56	0.12	0.11	0.26	0.01	0.45		-0.32	0.32	0.1	0.01	-0.36	0.28	0.34	0.57	0.55	0.1	-0.57
Gross Profit	0.59	0.53	0.46	0.01	0.41	0.39	0.29	0.01	0.34	-0.32		0.53	0.38	0.65	0.34	0.52	0.37	-0.25	-0.26	0.37	0.46
Other Operating Expenses	0.81	0.06	0.66	-0.72	0.74	0.71	0.72	0.11	0.84	0.32	0.53		0.68	0.59	-0.45	0.96	0.95	0.64	0.64	0.67	-0.24
Net Income From Continuing Ops	0.61	0.03	0.56	-0.42	0.98	0.99	0.48	-0.22	0.46	0.1	0.38	0.68		0.48	-0.37	0.6	0.69	0.37	0.4	1.0	-0.06
Ebit	0.47	0.26	0.25	-0.2	0.49	0.49	0.5	-0.42	0.28	0.01	0.65	0.59	0.48		0.09	0.67	0.59	0.15	0.14	0.47	0.12
Total Operating Expenses	-0.28	0.51	-0.46	0.65	-0.4	-0.39	-0.36	-0.35	-0.45	-0.36	0.34	-0.45	-0.37	0.09		-0.46	-0.45	-0.88	-0.89	-0.36	0.7
Total Other Income Expense Net	0.75	0.05	0.66	-0.67	0.66	0.63	0.73	0.2	0.71	0.28	0.52	0.96	0.6	0.67	-0.46		0.9	0.66	0.66	0.58	-0.23
Tax Provision	0.75	-0.06	0.5	-0.73	0.75	0.72	0.75	-0.07	0.76	0.34	0.37	0.95	0.69	0.59	-0.45	0.9		0.68	0.68	0.68	-0.32
Net Interest Income	0.36	-0.43	0.42	-0.8	0.42	0.4	0.55	0.24	0.59	0.57	-0.25	0.64	0.37	0.15	-0.88	0.66	0.68		1.0	0.36	-0.7
Interest Income	0.36	-0.44	0.43	-0.79	0.45	0.43	0.55	0.24	0.57	0.55	-0.26	0.64	0.4	0.14	-0.89	0.66	0.68	1.0		0.39	-0.73
Ebitda	0.6	0.04	0.54	-0.41	0.98	0.99	0.47	-0.24	0.45	0.1	0.37	0.67	1.0	0.47	-0.36	0.58	0.68	0.36	0.39		-0.05
Reconciled Depreciation	-0.05	0.42	-0.12	0.56	-0.09	-0.08	-0.24	-0.13	-0.28	-0.57	0.46	-0.24	-0.06	0.12	0.7	-0.23	-0.32	-0.7	-0.73	-0.05

Click cells to compare fundamentals

China Reform Account Relationship Matchups

China Reform income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	507.9K	2.5M	2.0M	5.1M	5.9M	6.2M
Selling General Administrative	39.7M	50.2M	53.2M	58.6M	52.8M	77.9M
Total Revenue	207.4M	252.5M	311.1M	330.1M	297.1M	199.0M
Operating Income	(117.4M)	(132.7M)	(109.9M)	(106.6M)	(95.9M)	(91.1M)
Cost Of Revenue	176.9M	218.7M	246.6M	248.1M	285.4M	299.6M
Income Before Tax	(242.8M)	(176.9M)	(83.2M)	(78.4M)	(70.6M)	(67.0M)
Net Income Applicable To Common Shares	17.4M	(242.6M)	(175.8M)	(84.5M)	(76.0M)	(72.2M)
Net Income	(242.6M)	(175.8M)	(84.5M)	(79.8M)	(71.8M)	(68.2M)
Income Tax Expense	506.2K	523.2K	203.3K	1.3M	1.1M	1.1M
Minority Interest	3.1M	1.3M	(7.3K)	527.5K	474.7K	451.0K
Research Development	16.4M	16.3M	9.6M	967.9K	871.2K	827.6K
Gross Profit	30.5M	33.8M	64.5M	82.0M	94.3M	99.0M
Other Operating Expenses	741.3K	943.2K	1.2M	1.0M	909.4K	864.0K
Net Income From Continuing Ops	(243.3M)	(177.1M)	(84.5M)	(80.3M)	(72.3M)	(75.9M)
Ebit	(173.1M)	(129.4M)	(132.7M)	(109.9M)	(98.9M)	(103.9M)
Total Operating Expenses	324.8M	385.3M	421.0M	436.7M	502.2M	364.3M
Tax Provision	523.2K	203.3K	1.3M	1.9M	1.7M	1.6M
Net Interest Income	7.5M	764.1K	(601.9K)	(4.7M)	(4.2M)	(4.0M)
Interest Income	8.2M	4.3M	1.6M	628.2K	565.4K	537.1K
Ebitda	48.8M	(210.0M)	(138.1M)	(41.6M)	(37.4M)	(39.3M)
Reconciled Depreciation	32.3M	36.3M	39.6M	33.8M	38.8M	37.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Other Information on Investing in China Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

China Historical Income Statement

About China Income Statement Analysis

China Reform Income Statement Chart

Total Revenue

Cost Of Revenue

China Reform income statement Correlations

China Reform Account Relationship Matchups

High Positive Relationship

High Negative Relationship

China Reform income statement Accounts

Also Currently Popular

Other Information on Investing in China Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 1.0	Income Before Tax
Ebitda	+ 1.0	Net Income From Continuing Ops
Interest Income	+ 1.0	Net Interest Income
Net Income From Continuing Ops	+ 0.99	Net Income
Ebitda	+ 0.99	Net Income
Net Income From Continuing Ops	+ 0.98	Income Before Tax

Interest Income	- 0.89	Total Operating Expenses
Net Interest Income	- 0.88	Total Operating Expenses
Net Interest Income	- 0.8	Cost Of Revenue
Interest Income	- 0.79	Cost Of Revenue
Reconciled Depreciation	- 0.73	Interest Income
Tax Provision	- 0.73	Cost Of Revenue